These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 34987510

  • 1. Different Effects of Biologics on Systemic Bone Loss Protection in Rheumatoid Arthritis: An Interim Analysis of a Three-Year Longitudinal Cohort Study.
    Chen MH, Yu SF, Chen JF, Chen WS, Liou TL, Chou CT, Hsu CY, Lai HM, Chen YC, Tsai CY, Cheng TT.
    Front Immunol; 2021; 12():783030. PubMed ID: 34987510
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Potential alleviation of bone mineral density loss with Janus kinase inhibitors in rheumatoid arthritis.
    Chen YW, Chen HH, Huang WN, Chen JP, Chen YH, Chen YM.
    Clin Rheumatol; 2024 Jan; 43(1):117-128. PubMed ID: 37658935
    [Abstract] [Full Text] [Related]

  • 4. Abatacept might increase bone mineral density at femoral neck for patients with rheumatoid arthritis in clinical practice: AIRTIGHT study.
    Tada M, Inui K, Sugioka Y, Mamoto K, Okano T, Koike T.
    Rheumatol Int; 2018 May; 38(5):777-784. PubMed ID: 29294175
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The limited effects of anti-tumor necrosis factor blockade on bone health in patients with rheumatoid arthritis under the use of glucocorticoid.
    Okano T, Koike T, Tada M, Sugioka Y, Mamoto K, Wakitani S, Nakamura H.
    J Bone Miner Metab; 2014 Sep; 32(5):593-600. PubMed ID: 24233123
    [Abstract] [Full Text] [Related]

  • 7. Conventional synthetic disease-modifying antirheumatic drugs and bone mineral density in rheumatoid arthritis patients with osteoporosis: possible beneficial effect of leflunomide.
    Kwon OC, Oh JS, Hong S, Lee CK, Yoo B, Kim YG.
    Clin Exp Rheumatol; 2019 Sep; 37(5):813-819. PubMed ID: 30767868
    [Abstract] [Full Text] [Related]

  • 8. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
    Finckh A, Tellenbach C, Herzog L, Scherer A, Moeller B, Ciurea A, von Muehlenen I, Gabay C, Kyburz D, Brulhart L, Müller R, Hasler P, Zufferey P, physicians and patients of the SCQM.
    RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
    [Abstract] [Full Text] [Related]

  • 9. The Impact of Seropositivity on Systemic Bone Loss in Rheumatoid Arthritis-A 3-Year Interim Analysis of a Longitudinal Observational Cohort Study.
    Yu SF, Chen JF, Chen YC, Wang YW, Hsu CY, Lai HM, He HR, Ko CH, Chiu WC, Cheng TT.
    Front Med (Lausanne); 2022 May; 9():885801. PubMed ID: 35755026
    [Abstract] [Full Text] [Related]

  • 10. Meta-analysis of tumor necrosis factor inhibitors and glucocorticoids on bone density in rheumatoid arthritis and ankylosing spondylitis trials.
    Siu S, Haraoui B, Bissonnette R, Bessette L, Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Kraft J, Lynde C, Gulliver W, Keeling S, Dutz J, Pope JE.
    Arthritis Care Res (Hoboken); 2015 May; 67(6):754-64. PubMed ID: 25418272
    [Abstract] [Full Text] [Related]

  • 11. Comparison of infection-related hospitalization risk and costs in tumor necrosis factor inhibitor-experienced patients with rheumatoid arthritis (RA) treated with abatacept or other targeted disease-modifying anti-rheumatic drugs (tDMARDs).
    Paul D, Patil D, McDonald L, Patel V, Lobo F.
    J Med Econ; 2020 Sep; 23(9):1025-1031. PubMed ID: 32427547
    [Abstract] [Full Text] [Related]

  • 12. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H, Frisell T, Askling J, Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group.
    JAMA Intern Med; 2017 Nov 01; 177(11):1605-1612. PubMed ID: 28975211
    [Abstract] [Full Text] [Related]

  • 13. Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry.
    Choquette D, Bessette L, Alemao E, Haraoui B, Postema R, Raynauld JP, Coupal L.
    Arthritis Res Ther; 2019 Jun 06; 21(1):138. PubMed ID: 31171024
    [Abstract] [Full Text] [Related]

  • 14. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss.
    Wijbrandts CA, Klaasen R, Dijkgraaf MG, Gerlag DM, van Eck-Smit BL, Tak PP.
    Ann Rheum Dis; 2009 Mar 06; 68(3):373-6. PubMed ID: 18408246
    [Abstract] [Full Text] [Related]

  • 15. Effects of 1-year anti-TNF-α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis.
    Gulyás K, Horváth Á, Végh E, Pusztai A, Szentpétery Á, Pethö Z, Váncsa A, Bodnár N, Csomor P, Hamar A, Bodoki L, Bhattoa HP, Juhász B, Nagy Z, Hodosi K, Karosi T, FitzGerald O, Szücs G, Szekanecz Z, Szamosi S, Szántó S.
    Clin Rheumatol; 2020 Jan 06; 39(1):167-175. PubMed ID: 31522318
    [Abstract] [Full Text] [Related]

  • 16. Association between Bone Mineral Density of Femoral Neck and Geriatric Nutritional Risk Index in Rheumatoid Arthritis Patients Treated with Biological Disease-Modifying Anti-Rheumatic Drugs.
    Tokumoto H, Tominaga H, Arishima Y, Jokoji G, Akimoto M, Ohtsubo H, Taketomi E, Sunahara N, Nagano S, Ishidou Y, Komiya S, Setoguchi T.
    Nutrients; 2018 Feb 18; 10(2):. PubMed ID: 29463015
    [Abstract] [Full Text] [Related]

  • 17. Biologic therapies and bone loss in rheumatoid arthritis.
    Zerbini CAF, Clark P, Mendez-Sanchez L, Pereira RMR, Messina OD, Uña CR, Adachi JD, Lems WF, Cooper C, Lane NE, IOF Chronic Inflammation and Bone Structure (CIBS) Working Group.
    Osteoporos Int; 2017 Feb 18; 28(2):429-446. PubMed ID: 27796445
    [Abstract] [Full Text] [Related]

  • 18. Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied?
    van der Goes MC, Jacobs JW, Jurgens MS, Bakker MF, van der Veen MJ, van der Werf JH, Welsing PM, Bijlsma JW.
    Osteoporos Int; 2013 Apr 18; 24(4):1429-36. PubMed ID: 23011680
    [Abstract] [Full Text] [Related]

  • 19. Use of bisphosphonate might be important to improve bone mineral density in patients with rheumatoid arthritis even under tight control: the TOMORROW study.
    Tada M, Inui K, Sugioka Y, Mamoto K, Okano T, Anno S, Koike T.
    Rheumatol Int; 2017 Jun 18; 37(6):999-1005. PubMed ID: 28405825
    [Abstract] [Full Text] [Related]

  • 20. Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs.
    Tawaratsumida H, Setoguchi T, Arishima Y, Ohtsubo H, Akimoto M, Ishidou Y, Nagano S, Taketomi E, Sunahara N, Komiya S.
    BMC Res Notes; 2017 Dec 21; 10(1):765. PubMed ID: 29268799
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.